Neurotech is pleased to announce they have signed Holy Stone Healthcare as the exclusive distributor in Taiwan.
Online PR News – 20-December-2019 – Malta and Perth, Australia – Holy Stone Healthcare was established in Taipei in January 2001 and is committed to developing lifesaving therapeutics and targeted delivery technologies to improve the quality of life of patients
The three-year agreement with Holy Stone Healthcare confirms exclusive distribution for the territory of Taiwan. The agreement is subject to successful approval from the TFDA which is anticipated to be
in the first quarter of 2020. The agreement is otherwise subject to standard commercial terms for contracts of this nature.
Clinically proven Mente helps children with ASD to learn to engage positively with their environment and self-regulate attention and mood. Details on Mente can be found at https://www.mentetech.com/.
Neurotech CEO, Peter Griffiths, said: "Our partnership with Holy Stone Healthcare demonstrates our commitment to provide the best service to our customers.
I am very pleased with the collaboration between the teams and we look forward to building a significant business with Holy Stone Healthcare
Albert Wu, CEO of Holy Stone Healthcare, said: "We are excited to be moving forward with this new endeavour, as this will now give our customers access to Mente's award-winning and clinically proven product across Taiwan."